Figure 2 presents the results for perimetry (CS measurements) as a function of luminance, for the foveal test location (
Fig. 2A), the peripheral test locations that were not blind (
Fig. 2B), and for the best-preserved peripheral test location in the glaucoma patients (
Fig. 2C). This best-preserved peripheral test location was (+3,−3) in all but six glaucoma patients; these six patients were excluded from
Figure 2C and the corresponding analysis (see below). At the lowest luminance, none but one glaucoma patient could see the central stimulus, and none but two glaucoma patients could see any peripheral stimulus, compared with approximately half of the controls. To maintain a sufficiently large number of complete cases for the ANOVA, we performed the ANOVA without the lowest luminance. LogCS was significantly influenced by luminance for both the glaucoma patients and the controls (
P < 0.001). Glaucoma patients had a lower logCS in the fovea, in the nonblind peripheral visual field, and in the best-preserved peripheral test location (all
P < 0.001), compared with the controls. The difference between glaucoma patients and controls was approximately 0.4 log units in the fovea, independent of luminance (no significant interaction between glaucoma and luminance;
P = 0.06). However, in the nonblind peripheral visual field and the best-preserved peripheral test location, the difference between glaucoma patients and controls was more pronounced at lower luminances (significant interaction between glaucoma and luminance;
P = 0.007 for the nonblind peripheral visual field;
P = 0.008 for the best-preserved peripheral test location). Between 0.13 and 1.3 cd/m
2, the slope of the foveal logCS as a function of log luminance curve was 0.53 for the glaucoma patients and 0.54 for the controls, which is close to the slope of 0.5 as predicted by the De Vries-Rose law. At higher luminances, the CS started to saturate, which is in agreement with Weber's law. In the same luminance range (0.13–1.3 cd/m
2), the slope of the curve of the nonblind peripheral visual field was 0.31 for the glaucoma patients and 0.38 for the controls. For the best-preserved peripheral test location, the slope was 0.30 for the glaucoma patients and 0.39 for the controls. At higher luminances, the peripheral CS started to saturate for the controls, but (within our luminance range) not for the glaucoma patients. Below 0.13 cd/m
2, the slope appeared to be steeper than 0.5 for the controls, especially in the fovea. As mentioned above, most of the glaucoma patients were unable to see the stimulus below this luminance.